Endothelin Pathway: Function, Receptors, and Clinical Significance

The endothelin pathway is a signaling pathway involving the production and action of endothelin proteins. Endothelins are a family of peptides that are primarily produced by endothelial cells, which line the inner walls of blood vessels.

The pathway begins with the production of preproendothelin, a precursor protein, which is then cleaved to form big endothelin. Big endothelin is further cleaved by the enzyme endothelin-converting enzyme (ECE) to produce the active endothelin-1 peptide.

Endothelin-1 acts on two types of receptors known as endothelin receptor type A (ETA) and endothelin receptor type B (ETB). ETA receptors are mainly present on smooth muscle cells in blood vessels and are responsible for vasoconstriction, which narrows the blood vessels. On the other hand, ETB receptors are found on both endothelial cells and smooth muscle cells and have dual actions. They can cause vasoconstriction similar to ETA receptors, but they can also cause vasodilation by releasing nitric oxide and prostacyclin from endothelial cells.

The activation of ETA receptors by endothelin-1 leads to increased intracellular calcium levels in smooth muscle cells, which results in the contraction of blood vessels. This vasoconstriction can contribute to increased blood pressure and reduced blood flow to various organs.

The activation of ETB receptors, particularly on endothelial cells, stimulates the release of nitric oxide and prostacyclin. Nitric oxide relaxes smooth muscle cells, leading to vasodilation and increased blood flow. Prostacyclin also promotes vasodilation and inhibits platelet aggregation, further enhancing blood flow.

The endothelin pathway is involved in various physiological and pathological processes, including blood pressure regulation, cardiovascular development, and the pathogenesis of conditions such as hypertension, heart failure, and pulmonary hypertension. Modulating the endothelin pathway through pharmacological agents targeting endothelin receptors or endothelin-converting enzyme has been explored as a potential therapeutic approach for these conditions.